drugset / Trial / NCT06812715
Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib
Phase 2
Recruiting
40 enrolled
Peter MacCallum Cancer Centre, Australia
Eli Lilly and Company · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a multicentre single-arm prospective phase II trial evaluating pirtobrutinib in the treatment of relapsed/refractory (R/R) Chronic Lymphocytic Leukaemia (CLL) patients who have previously received zanubrutinib, and to specifically evaluate Bruton Tyrosine Kinase (BTK) mutational status (clonal dynamics) before, during and after treatment with pirtobrutinib.
Timeline
- Start
- 2025-05-05
- Primary completion
- 2029-05
- Completion
- 2031-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pirtobrutinib | Other / unclassified | 200 mg | Oral |